Washington, DC 20549
|
FORM
|
CURRENT REPORT
|
Date of Report (Date of earliest event reported):
|
|
(Exact name of Registrant as specified in its charter)
|
|
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
Item 8.01 |
Other Events.
|
Dated: April 13, 2023
|
||
Aquestive Therapeutics, Inc.
|
||
By:
|
/s/ A. Ernest Toth, Jr
|
|
Name: A. Ernest Toth, Jr.
|
||
Title: Chief Financial Officer
|